Press Releases

 
Featured
Oak Hill Bio and Chiesi Group Announce First European Patient Enrolled in the Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Premature Infants
Oak Hill Bio Announces Promotion of Josh Distler to Chief Executive Officer and Additional Updates to Executive Team and Board 
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Premature Infants
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
Oak Hill Bio to Participate in Citi 17th Annual BioPharma Conference
Oak Hill Bio Joins C-Path’s International Neonatal Consortium
Oak Hill Bio to Participate in 2022 Wells Fargo Private Biotech Symposium
Oak Hill Bio Sponsors Industry Symposium at International Conference on Clinical Neonatology
2022 RBC Capital Markets Global Healthcare Conference
Oak Hill Bio to Present at 2022 RBC Capital Markets Global Healthcare Conference
Oak Hill Bio Launches with Pipeline and Senior Leadership from Takeda

In the News